Identification
Name Mepivacaine
Accession Number DB00961 (APRD01094)
Type small molecule
Description A local anesthetic that is chemically related to bupivacaine but pharmacologically related to lidocaine. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168)
Structure
Categories (*)
Molecular Weight 246.348
Groups approved
Monoisotopic Weight 246.173213336
Pharmacology
Indication For production of local or regional analgesia and anesthesia by local infiltration, peripheral nerve block techniques, and central neural techniques including epidural and caudal blocks.
Mechanism of action Local anesthetics block the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers. Clinically, the order of loss of nerve function is as follows: pain, temperature, touch, proprioception, and skeletal muscle tone.
Absorption Absorbed locally. The rate of systemic absorption of local anesthetics is dependent upon the total dose and concentration of drug administered, the route of administration, the vascularity of the administration site, and the presence or absence of epinephrine in the anesthetic solution.
Protein binding Mepivacaine is approximately 75% bound to plasma proteins. Generally, the lower the plasma concentration of drug, the higher the percentage of drug bound to plasma.
Biotransformation Rapidly metabolized, with only a small percentage of the anesthetic (5 percent to 10 percent) being excreted unchanged in the urine. The liver is the principal site of metabolism, with over 50% of the administered dose being excreted into the bile as metabolites.
Route of elimination It is rapidly metabolized, with only a small percentage of the anesthetic (5 percent to 10 percent) being excreted unchanged in the urine.The liver is the principal site of metabolism, with over 50% of the administered dose being excreted into the bile as metabolites.
Toxicity The mean seizure dosage of mepivacaine in rhesus monkeys was found to be 18.8 mg/kg with mean arterial plasma concentration of 24.4 µg/mL. The intravenous and subcutaneous LD 50 in mice is 23 mg/kg to 35 mg/kg and 280 mg/kg respectively.
Affected organisms
  • Humans and other mammals
Interactions
Drug Interactions Not Available
Food Interactions Not Available
Sodium channel protein type 10 subunit alpha
Name Sodium channel protein type 10 subunit alpha
Gene Name SCN10A
Pharmacological action yes
Actions inhibitor
References
  • Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. - Pubmed
  • Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. - Pubmed
  • Leffler A, Reckzeh J, Nau C: Block of sensory neuronal Na+ channels by the secreolytic ambroxol is associated with an interaction with local anesthetic binding sites. Eur J Pharmacol. 2010 Mar 25;630(1-3):19-28. Epub 2010 Jan 4. - Pubmed
DTHybrid score 0.5958
Id Partner name Gene Name Score
220 Sodium channel protein type 5 subunit alpha SCN5A 0.0589
3923 Cholinesterase BCHE 0.0576
1995 Sodium channel protein type 9 subunit alpha SCN9A 0.0381
3803 Sodium channel protein type 3 subunit alpha SCN3A 0.0379
4512 Cytochrome P450 3A4 CYP3A4 0.0319
4200 Cytochrome P450 1A2 CYP1A2 0.0312
706 Glutamate [NMDA] receptor subunit 3A GRIN3A 0.0296
713 Sodium-dependent dopamine transporter SLC6A3 0.0249
341 5-hydroxytryptamine 3 receptor HTR3A 0.0229
4604 Liver carboxylesterase 1 CES1 0.0215
4119 Cytochrome P450 2D6 CYP2D6 0.0192
6030 Cytochrome P450 2B6 CYP2B6 0.0168
465 Calmodulin CALM1 0.0163
1588 Multidrug resistance protein 1 ABCB1 0.0153
73 Prostaglandin E2 receptor, EP1 subtype PTGER1 0.014
458 Neuronal acetylcholine receptor subunit alpha-10 CHRNA10 0.0138
813 Neuronal acetylcholine receptor subunit alpha-2 CHRNA2 0.0108
540 Sodium-dependent noradrenaline transporter SLC6A2 0.0095
439 Glutamate [NMDA] receptor subunit epsilon-4 GRIN2D 0.0091
591 Glutamate [NMDA] receptor subunit 3B GRIN3B 0.0083
401 Glutamate [NMDA] receptor subunit zeta-1 GRIN1 0.008
215 Sodium channel protein type 11 subunit alpha SCN11A 0.0075
6016 Cytochrome P450 2C19 CYP2C19 0.0069
6107 Cytochrome P450 3A7 CYP3A7 0.0059
4118 Cytochrome P450 3A5 CYP3A5 0.0056
4924 Cytochrome P450 2C8 CYP2C8 0.0055
844 Epidermal growth factor receptor EGFR 0.0053
4757 Cytochrome P450 2C9 CYP2C9 0.0051
492 Histamine H1 receptor HRH1 0.0051
6013 Cytochrome P450 2E1 CYP2E1 0.0046
6106 Cytochrome P450 2C18 CYP2C18 0.004
824 Sodium-dependent serotonin transporter SLC6A4 0.0038
617 Muscarinic acetylcholine receptor M2 CHRM2 0.0036
6144 Solute carrier family 22 member 2 SLC22A2 0.0035
103 Muscarinic acetylcholine receptor M1 CHRM1 0.0034
118 Organic cation/carnitine transporter 2 SLC22A5 0.0034
5718 Cytochrome P450 2A6 CYP2A6 0.0032